Literature DB >> 27721044

Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies.

Łukasz Fijałkowski1, Kinga Sałat2, Adrian Podkowa2, Paula Zaręba3, Alicja Nowaczyk4.   

Abstract

The chemical interaction of nine antiepileptic drugs (tiagabine, gabapentin, pregabalin, lamotrigine, zonisamide, valproic acid, valpromide, vigabatrin, progabide) and two endogenous metabolites (4-aminobutanoic acid, 4-hydroxybutanoic acid) with a model of human GABA transporter 1 (hGAT1) is described using the molecular docking method. To establish the role of hGAT1 in chronic pain, tiagabine, a selective hGAT1 inhibitor, was assessed in the in vivo experiments for its antiallodynic properties in two mouse models of neuropathic pain. Docking analyses performed in this study provided the complex binding energies, specific hydrogen bond components, and hydrogen bond properties such as energies, distances and angles. The data of the docking studies strongly support the assumption that the antiepileptic and analgesic actions of the studied drugs can be at least in part related to the strength of their chemical interactions with hGAT1. In vivo experiments with tiagabine confirmed the involvement of hGAT1 in the regulation of the mechanical nociceptive threshold in neuropathic pain.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analgesic activity; Antiepileptic drugs; GABA; GHB; Gabapentin (PubChem CID: 6453919); Lamotrigine (PubChem CID: 3878); Molecular docking; Pregabalin (PubChem CID: 5486971); Progabide (PubChem CID: 5361323); R-tiagabine (PubChem CID: 60648); S-tiagabine (PubChem CID: 10452119); Valproic (PubChem CID: 3121); Valpromide (PubChem CID: 71113); Vigabatrin (PubChem CID: 5665); Zonisamide (PubChem CID: 5734); hGAT1

Mesh:

Substances:

Year:  2016        PMID: 27721044     DOI: 10.1016/j.ejps.2016.10.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  8 in total

1.  Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive, and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain.

Authors:  Misty D Smith; Jose H Woodhead; Laura J Handy; Timothy H Pruess; Fabiola Vanegas; Erin Grussendorf; Joel Grussendorf; Karen White; Karolina K Bulaj; Reisa K Krumin; Megan Hunt; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-05-15       Impact factor: 3.996

2.  Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany.

Authors:  Brendan J Snellgrove; Tilman Steinert; Susanne Jaeger
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

3.  Gabapentin Prevents Progressive Increases in Excitatory Connectivity and Epileptogenesis Following Neocortical Trauma.

Authors:  D K Takahashi; Sha Jin; D A Prince
Journal:  Cereb Cortex       Date:  2018-08-01       Impact factor: 5.357

Review 4.  Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.

Authors:  Yang Yang; Bing Zhao; Xuejiao Gao; Jinbing Sun; Juan Ye; Jun Li; Peng Cao
Journal:  J Exp Clin Cancer Res       Date:  2021-10-22

5.  Assessment of Paroxetine Molecular Interactions with Selected Monoamine and γ-Aminobutyric Acid Transporters.

Authors:  Magdalena Kowalska; Łukasz Fijałkowski; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

Review 6.  Chemotherapy-induced peripheral neuropathy: part 1-current state of knowledge and perspectives for pharmacotherapy.

Authors:  Kinga Sałat
Journal:  Pharmacol Rep       Date:  2020-05-11       Impact factor: 3.024

7.  N-Substituted Nipecotic Acids as (S)-SNAP-5114 Analogues with Modified Lipophilic Domains.

Authors:  Michael C Böck; Georg Höfner; Klaus T Wanner
Journal:  ChemMedChem       Date:  2020-04-07       Impact factor: 3.466

Review 8.  Experimental Drugs for Neuropathic Pain.

Authors:  Kinga Salat; Beata Gryzlo; Katarzyna Kulig
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.